Mechanisms of Biofilm-Mediated Antibiotic Resistance in Clinical Pathogens

Abstract

Bacterial biofilms represent a critical challenge in clinical medicine, contributing to persistent infections that resist conventional antibiotic therapy. These structured microbial communities, encased in self-produced extracellular polymeric substances, exhibit resistance levels up to 1,000-fold higher than their planktonic counterparts. Understanding the molecular mechanisms underlying biofilm-mediated antibiotic resistance is essential for developing effective therapeutic strategies against chronic and device-associated infections. This review synthesizes current knowledge on the mechanisms by which biofilms confer antibiotic resistance in clinically relevant pathogens, examines the clinical implications of biofilm-associated infections, and evaluates emerging therapeutic strategies targeting biofilm-mediated resistance. A comprehensive analysis of peer-reviewed literature was conducted, focusing on molecular mechanisms of biofilm resistance, clinical pathogen characteristics, and novel therapeutic approaches. Studies examining physical barriers, metabolic adaptations, genetic regulation, and anti-biofilm strategies were systematically reviewed. Multiple interconnected mechanisms contribute to biofilm-mediated antibiotic resistance, including physical diffusion barriers created by the extracellular matrix, upregulation of efflux pump systems, formation of metabolically dormant persister cells, quorum sensing-mediated gene regulation, horizontal gene transfer of resistance determinants, and metabolic heterogeneity within biofilm structures. Key clinical pathogens including Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli, and Enterococcus faecalis employ these mechanisms in various infection contexts, from chronic wounds to medical device-associated infections.